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ABSTRACT
Objective To investigate the possibility that statins
reduce blood pressure as well as cholesterol
concentrations through clinic and 24 hour ambulatory
blood pressure monitoring.
DesignRandomisedplacebocontrolleddoubleblindtrial.
Setting 13 hospitals in Italy
Participants 508 patients with mild hypertension and
hypercholesterolaemia, aged 45 to 70 years.
Intervention Participants were randomised to
antihypertensive treatment (hydrochlorothiazide 25 mg
once daily or fosinopril 20 mg once daily) with or without
the addition of a statin (pravastatin 40 mg once daily).
Main outcome measures Clinic and ambulatory blood
pressure measured every year throughout an average 2.
6 year treatment period.
Results Both the group receiving antihypertensive
treatmentwithoutpravastatin(n=254)(withlittlechangein
total cholesterol) and the group receiving antihypertensive
treatment with pravastatin (n=253) (with marked and
sustained reduction in total cholesterol and low density
lipoproteincholesterol)hadaclearcutsustainedreduction
in clinic measured systolic and diastolic blood pressure as
wellasin 24hour,andday andnight, systolicanddiastolic
blood pressure. Pravastatin performed slightly worse than
placebo,andbetweengroupdifferencesdidnotexceed1.9
(95% confidence interval −0.6 to 4.3, P=0.13) mm Hg
throughout the treatment period. This was also the case
when participants who remained on monotherapy with
hydrochlorothiazide or fosinopril throughout the study
were considered separately.
Conclusions Administration of a statin in hypertensive
patientsinwhombloodpressureiseffectivelyreducedby
concomitantantihypertensivetreatmentdoesnothavean
additional blood pressure lowering effect.
Trial registration BRISQUI_*IV_2004_001 (registered at
OsservatorioNazionalesullaSperimentazioneClinicadei
Medicinali—National Monitoring Centre on Clinical
Research with Medicines).
INTRODUCTION
Two main mechanisms have been proposed for the
protection offered by statins against cardiovascular
disease. Firstly, statins reduce the incidence of morbid
andfatalcardiovasculareventsbyloweringtotalserum
cholesterol and, more generally, by reducing the com-
ponents of blood lipids that importantly contribute to
cardiovascular risk.
12Secondly, in addition to causing
changes in the lipid profile, statins may have pleiotro-
pic (for example, anti-inflammatory and anti-
proliferative) effects that directly protect tissues and
organs from cardiovascular risk factors.
3-9
In the past few years a third mechanism for the
cardiovascular protective effects of statins has been
proposed—that statins may also lower blood pressure
and thus act through a reduction in the blood pressure
related risk. However, many of studies on which this
hypothesis is based have important limitations,
10-17 as
has their meta-analysis.
18 These include the uncon-
trollednatureoftheexperimentaldesign,retrospective
analysis of the data, the small number of participants
included, and the short follow-up. Furthermore, avail-
able data are largely limited to blood pressure mea-
sured in the clinic without providing information on
ambulatory blood pressure, which is of greater prog-
nostic importance.
19-21 This limitation applies also to a
large scale, long term, placebo controlled study in
which addition of a statin to two effective anti-
hypertensive treatment regimens was accompanied a
very small (about 1 mm Hg) further blood pressure
lowering effect.
22
In the PHYLLIS (Plaque Hypertension Lipid-
Lowering Italian Study) multicentre (13 centres)
trial,
23 more than 500 patients with mild hypertension
and hypercholesterolaemia were randomised to
administration of hydrochlorothiazide or fosinopril,
each of them with and without the addition of pravas-
tatin, in a placebo controlled, double blind, double
dummyfactorialdesign,todeterminewhichtherapeu-
tic approach could more effectively prevent carotid
artery atherosclerosis. The results, reported in detail
previously,
23 showed that progression of carotid
intima-media thickness was slowed by fosinopril com-
pared with hydrochlorothiazide or by the addition of
pravastatin compared with placebo to the hydrochlor-
othiazide treatment regimen. However, the PHYLLIS
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analysis of a comparison of the effects on blood pres-
sure of the antihypertensive agents compared, in com-
bination with either pravastatin or placebo, because
the treatment induced effects on blood pressure were
important for the interpretation of the changes in car-
otid intima-media thickness. This analysis was based
on the 24 hour ambulatory blood pressure data
obtained in all patients at yearly intervals throughout
the approximate three year duration of the trial.
Ambulatory blood pressure values were particularly
suited for this purpose because, compared with blood
pressuremeasurementsmade in the clinic, theyhave a
superior reproducibility and thus a greater ability to
detect small differences in blood pressure between
groups.
19-21 We report here the results of this analysis.
METHODS
The design and methods of PHYLLIS have been
described in detail elsewhere.
23 Briefly, men and post-
menopausalwomenaged45-70yearswererecruitedin
13 Italian hospitals if they had no history of cardio-
vascular events together with untreated or uncon-
trolled hypertension, hypercholesterolaemia, and
asymptomaticcarotidarteryatherosclerosis,identified
ultrasonographically.
Patientswhogaveaninformedwrittenconsenthada
six week washout with triple placebo, during which
they were given the American Heart Association low
lipid diet.
24 Patients who still had high clinic measured
blood pressure (systolic 150-210 mm Hg; diastolic 95-
115 mm Hg), high serum concentration of low density
lipoprotein cholesterol (4.14-5.17 mmol/l (160-
200 mg/dl)), and a serum triglyceride concentration
of 3.39 mmol/l or lower (≤300 mg/dl) were rando-
mised to four types of double blind, double dummy
treatment according to a factorial design: hydrochlor-
othiazide25mgoncedailyplusfosinoprilplaceboand
pravastatin placebo; fosinopril 20 mg once daily plus
hydrochlorothiazide placebo and pravastatin placebo;
hydrochlorothiazide 25 mg once daily plus fosinopril
placebo and pravastatin 40 mg; and fosinopril 20 mg
once daily plus hydrochlorothiazide placebo and pra-
vastatin 40 mg once daily. Each study treatment was
placedinanumberedcontaineraccordingtoacompu-
ter generated randomisation procedure with a block
size of four. If after three months clinic diastolic
blood pressure was not less than 90 mm Hg or less
than 95 mm Hg with a fall of at least 10 mm Hg, open
labelnifedipineGITS(gastrointestinaltherapeuticsys-
tem) 30 mg once daily was added, to be eventually
increasedto60mgoncedailyaftersixmonthsifneces-
sary. Nifedipine GITS was selected because calcium
antagonists are lipid neutral. The low lipid diet and
drug treatment were maintained throughout the fol-
low-up period (mean of 2.6 years). Patients and study
personnel (local investigators, core laboratory readers
of carotid ultrasound or ambulatory blood pressure
monitoringdata)were blindedtotreatmentallocation.
Measurements
Measurements consisted of carotid artery wall thick-
nessbyultrasonography,lipidprofile(serumtotalcho-
lesterol, low density lipoprotein cholesterol, high
densitylipoproteincholesterol,andtriglycerides),fast-
ing blood glucose and other blood chemistry values,
clinic blood pressure, and ambulatory blood pressure.
Thelipidprofilewasassessedatbaseline,threemonths
afterthestartoftreatment,andatyearlyintervalsthere-
after. For each patient, trained personnel measured
blood pressure in the clinic before randomisation to
treatment and at visits after three months and at yearly
intervals during treatment. On each occasion, three
measurements were made over five minutes with a
mercury sphygmomanometer after the patient had
been seated comfortably for at least five minutes. We
used the average of the three systolic and diastolic
blood pressurevaluesfor data analyses. We calculated
pulsepressureasthedifferencebetweensystolicblood
pressure and diastolic blood pressure. We calculated
heart rate from the radial pulse during 30 seconds. A
24 hour ambulatory blood pressure recording was
obtained immediately before randomisation to treat-
ment and at yearly intervals during treatment. The
recordings were not spaced by more than a week
fromthecorrespondingclinicbloodpressuremeasure-
ments. Each ambulatory blood pressure recording
began in the morning, after the study drugs were
taken, using validated devices,
2526 and after a check
had been made to show that the patient’s readings
did not differ by more than 5 mm Hg from simulta-
neously obtained auscultatory readings. The devices
were programmed to provide automatic readings
every 15 minutes during the day (from 6 am to mid-
night) and every 20 minutes during the night (from
midnightto6am).Patientswereinstructedtocontinue
theirusualactivitiesduringtherecordingperiodbutto
avoidstrenuousexerciseandtokeepthearmextended
and still during the automatic cuff inflations. The
ambulatory blood pressure data were sent to a core
laboratory (Istituto Auxologico Italiano, Milan, Italy)
for analysis, which was done only if valid ambulatory
blood pressure readings, identified according to pre-
defined criteria,
27 formed at least 70% of the expected
number of readings and at least one reading per hour
for at least 21 hours was available. We calculated 24
hour, daytime, and night-time average systolic, diasto-
lic, and pulse pressures; day-night differences in systo-
lic, diastolic, and pulse pressures; and standard
deviation of 24 hour systolic blood pressure, which
we took as an index of blood pressure variability.
28
We also calculated clinic and ambulatory values for
heart rate. Ultrasonographers and personnel who
read ambulatory blood pressure were kept blinded to
lipid concentrations throughout the study.
Statistical analysis
The main end point of this analysis (and a secondary
end point of the main study) was the comparison
between the reduction in 24 hour ambulatory blood
pressureinthegroupswithandwithoutadministration
RESEARCH
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pant’s systolic blood pressure values over 24 hours in
the baseline condition and three times during treat-
ment—that is, after 12 months, after 24 months, and
at the end of the study. We also did this for diastolic
bloodpressure,pulsepressure,andheartrate.Wealso
calculated daytime average, night-time average, and
clinic measured values. We assessed differences
between on-treatment and baseline values by aver-
agingallon-treatmentdataandbyseparatelyconsider-
ing values obtained at the three different times during
treatment. We did a separate analysis on the subgroup
of patients who remained on monotherapy for the
whole duration of the study. We used a paired t test
to compare averaged on-treatment and baseline
blood pressure values and an unpaired t test for
between group comparisons. We also did this for
other (for example, metabolic) data. We used a
repeated measures analysis of covariance model to
test the time (within participant) effect and the pravas-
tatin (between groups) effect. We adjusted the analysis
for concomitant nifedipine treatment and for baseline
values. We subsequently included an interaction term
in the model, to test whether the pravastatin effect dif-
fered accordingto baselinevalues. We pooled data for
the two groups taking antihypertensive treatment
(hydrochlorothiazide or fosinopril) without pravasta-
tin and compared them with the pooled data of the
two groups taking antihypertensive treatment plus
pravastatin.
23 We did the analyses on an intention to
treat basis. We always took P<0.05 as the level of sta-
tistical significance. All significance tests were two
sided. We present data as means and standard devia-
tions or means and 95% confidence intervals.
The sample size for the PHYLLIS study was origin-
ally calculated on the basis of the hypothesis made for
changesin carotidintima-mediathickness—that is,the
primary outcome.
23 For this pre-specified secondary
analysis, we provide a post hoc power calculation.
The two groups (with and without pravastatin) com-
pared for blood pressure response were of a size (254
v 253 patients) sufficient to detect, with 90% power, a
difference of 4.04 mm Hg in 24 hour average systolic
blood pressure, with α=0.05, assuming a standard
deviation of 14.0 mm Hg.
RESULTS
Figure 1 shows the flow of participants in the study
(considering only the randomisation to pravastatin or
corresponding placebo). Recruitment started in April
1995 and was completed in May 1997, and the follow-
upofthelastparticipantswascompletedinNovember
1999.Throughoutthestudy,26seriousadverseevents
occurred(14intheplacebogroupand12inthepravas-
tatin group); the number of patients lost to follow-up
was 23 in the placebo group and 30 in the pravastatin
group.Table 1showsthatatbaselinethepatientsinthe
two groups were matched for demographic character-
istics, blood chemistry, and blood pressure values.
Ambulatory blood pressure recordings were not ana-
lysed in 24 cases because they did not meet the study
quality criteria.
As shown in figure 2, in both groups anti-
hypertensive treatment with fosinopril or hydrochlor-
othiazide was associated with a sustained reduction in
24 hour, day, night, and clinic systolic and diastolic
blood pressure values, which was statistically signifi-
cant at all times compared with baseline values. On-
treatmentbloodpressureswere neversignificantlydif-
ferent between groups with and without pravastatin.
Table 2 shows the data obtained by comparing the
averaged on-treatment values with those at baseline.
The reduction in 24 hour systolic blood pressure
(pool of all on-treatment values) from baseline values
tended to be smaller in patients receiving anti-
hypertensive treatment plus pravastatin than in those
receiving antihypertensive treatment and placebo,
althoughthedifference wasnotstatisticallysignificant.
This was also the case for daytime, night-time, and
clinic measured systolic blood pressure, as well as for
diastolic pressure and pulse pressure. Neither treat-
ment significantly affected heart rate values.
Repeated measures analysis of covariance yielded
very similar results, with a strong effect of time
(P<0.001 for all blood pressure measures) and a non-
significanteffectofpravastatin(exceptforaborderline
effect(P=0.06)on24hoursystolicbloodpressure,indi-
catingaslightlysmallerbloodpressurereductioninthe
pravastatin group). When we considered only on-
treatment measures, we found no significant time
effect, indicating a fairly stable blood pressure reduc-
tion in both groups. Moreover, in the pravastatin
group all interactions with baseline values were non-
significant (systolic blood pressure, P=0.16; diastolic
blood pressure, P=0.99; pulse pressure, P=0.08). The
Allocated to placebo (n=254):
  Received allocated intervention (n=254)
  Did not receive allocated intervention (n=0)
Allocated to pravastatin (n=254):
  Received allocated intervention (n=253)
  Did not receive allocated intervention (n=1)
Assessed for eligibility (n=950)
Enrolment
Randomisation
Excluded (n=442):
  Did not meet inclusion criteria (n=395)
  Refused to participate (n=36)
  Other reasons (n=11)
Allocation
Lost to follow-up (n=30):
  Withdrew consent (n=30)
Discontinued intervention (n=0)
Lost to follow-up (n=18):
  Withdrew consent (n=18)
Discontinued intervention (n=5):
  Adverse events (n=5)
Follow-up
Analysed (n=230)
Excluded from analysis (n=0)
Analysed (n=224)
Excluded from analysis (n=0)
Analysis
Fig 1 | Flow of participants in study (for purposes of analysis reported here, only randomisation
to pravastatin or corresponding placebo is considered)
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also did not differ significantly between the groups
with pravastatin or placebo. Heart rate values were
also never significantly modified by treatment either
with or without pravastatin.
The large majority of patients remained on anti-
hypertensive monotherapy with either hydrochlor-
othiazide or fosinopril both in the placebo group
(88%) and in the pravastatin group (87%). As shown
in table 3, when we limited the analysis to the partici-
pants who remained on monotherapy, the reduction
from baseline in ambulatory and clinic blood pressure
did not differ significantly between groups receiving
pravastatin or placebo. This was also the case when
weadjustedthedataforthesmalldifferenceinthepro-
portion of patients on antihypertensive monotherapy
between the two groups. Moreover, in a time to event
Kaplan-Meier analysis, we found no significant differ-
encebetweenthetwogroupsinthenumberofpatients
who needed open label nifedipine (log-rank test
χ
2=0.93, P=0.33). Finally, when we compared clinic
blood pressure values at three months (when all
patientswereontheinitialantihypertensivemonother-
apy),wealsofoundnodifferenceinsystolicanddiasto-
licbloodpressurebetweentheplaceboandpravastatin
groups(systolic144.8and144.8mmHg;diastolic88.1
and 87.8 mm Hg) (fig 2).
Figure 3 shows the lipid concentrations throughout
the study. In the groups taking hydrochlorothiazide or
fosinopril plus placebo, serum total cholesterol and
low density lipoprotein cholesterol showed only
minor changes, whereas in the groups in which one
or other antihypertensive treatment was combined
with the administration of pravastatin, both showed a
sustainedsignificantdecrease.Differencesbetweenthe
groups with and without pravastatin (about 1 mmol/l)
were highly significant throughout the treatment per-
iod (P<0.001).
DISCUSSION
In patients with mild hypertension and hypercholes-
terolaemia, antihypertensive treatment with a thiazide
diureticoranangiotensinconvertingenzymeinhibitor
effectively lowered clinic measured and ambulatory
blood pressure over a time interval of approximately
threeyears.Comparedwithadministrationofplacebo,
addition of pravastatin to the antihypertensive treat-
ment caused a marked and sustained reduction in
serum total cholesterol and low density lipoprotein
cholesterol. This addition, however, did not cause
any further reduction in systolic or diastolic blood
pressure values, either when they were measured at
regular intervals in the physician’s office or when
they were repeatedly assessed on an ambulatory basis
over24hours.Thisprovidesevidenceagainstanysub-
stantial blood pressure lowering effect of statins in
patients with high blood pressure, suggesting that the
protective effects of these drugs on the cardiovascular
systemdonotdependonareductioninthebloodpres-
sure related risk of cardiovascular disease.
Strengths and limitations of study
PHYLLIS has several characteristics that make its
results robust. Firstly, the study had a prospective ran-
domised double blind design, which guarantees
against errors due to inappropriate matching of
patients and selection bias of patients or physicians.
Secondly, the study had a relatively long duration,
which allowed us to determine both the early effect
andthepossibledelayedeffectofstatinsonbloodpres-
sure. Thirdly, the effects of administration of statin on
blood pressure were regularly assessed by ambulatory
blood pressuremonitoring—that is, by a method char-
acterised by greater reproducibility than clinic blood
pressure measurements,
1920 and thus by a greater abil-
ity(becauseofareductionofbackgrounderraticblood
pressurechanges)todetectsmallbloodpressurediffer-
ences between treatment groups.
21 Fourthly, the
absence of any effect of statins on blood pressure was
also shown on additional blood pressure variables,
which have been shown to have an independent
Table 1 |Baseline characteristics of hypertensive patients randomised to pravastatin or
placebo. Values are mean (SD) unless stated otherwise
Characteristics Placebo (n=254) Pravastatin (n=253) P value
No (%) male 155 (61) 148 (59) 0.56
Age (years) 58.3 (6.5) 58.5 (6.8) 0.81
Weight (kg) 69.3 (10.9) 70.4 (11.2) 0.28
No (%) current smokers 45 (18) 41 (16) 0.65
Total cholesterol (mmol/l) 6.78 (0.66) 6.79 (0.68) 0.88
LDL cholesterol (mmol/l) 4.68 (0.53) 4.70 (0.50) 0.59
HDL cholesterol (mmol/l) 1.38 (0.33) 1.35 (0.35) 0.48
Triglycerides (mmol/l) 1.59 (0.57) 1.60 (0.62) 0.92
Glucose (mmol/l) 5.21 (0.65) 5.22 (0.78) 0.82
Creatinine (µmol/l) 83.0 (16.0) 83.0 (16.0) 0.91
Clinic measurements:
Systolic blood pressure (mm Hg) 160.0 (9.1) 159.6 (8.9) 0.66
Diastolic blood pressure (mm Hg) 98.3 (4.4) 98.3 (4.1) 0.93
Pulse pressure (mm Hg) 61.7 (8.5) 61.4 (8.1) 0.67
Heart rate (beats/min) 73.1 (7.4) 72.4 (7.3) 0.34
24 hour ambulatory measurements:
Systolic blood pressure (mm Hg) 136.4 (14.1) 136.2 (14.0) 0.87
Diastolic blood pressure (mm Hg) 84.5 (10.7) 83.5 (9.3) 0.28
Pulse pressure (mm Hg) 51.9 (9.2) 52.7 (9.7) 0.37
Heart rate (beats/min) 73.2 (8.4) 72.6 (7.5) 0.37
Daytime measurements:
Systolic blood pressure (mm Hg) 139.3 (14.6) 139.1 (14.4) 0.86
Diastolic blood pressure (mm Hg) 87.2 (11.1) 86.1 (9.7) 0.27
Pulse pressure (mm Hg) 52.2 (9.3) 53.0 (9.8) 0.35
Heart rate (beats/min) 75.6 (8.6) 75.0 (7.8) 0.44
Night time measurements:
Systolic blood pressure (mm Hg) 124.8 (15.0) 125.0 (14.7) 0.88
Diastolic blood pressure (mm Hg) 74.1 (10.7) 73.6 (9.5) 0.60
Pulse pressure (mm Hg) 50.7 (9.6) 51.4 (10.0) 0.45
Heart rate (beats/min) 64.2 (8.6) 63.2 (7.9) 0.22
HDL=high density lipoprotein; LDL=low density lipoprotein.
P values are for differences between groups; 24 hour, daytime, and night-time values are means for each
period.
RESEARCH
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sure and blood pressure variability.
27-30
Our study has also some limitations. One limitation
is that the design of PHYLLIS allowed the initial anti-
hypertensive treatment to be complemented by the
administration of open label nifedipine GITS at
increasing doses in the absence of blood pressure con-
trol or of a satisfactory blood pressure response. This
could have introduced a confounding factor, as the
absence of a blood pressure lowering effect of pravas-
tatin in patients on placebo might have been compen-
sated by more common addition of a second
antihypertensive drug. However, in PHYLLIS the
vast majority of the patients (almost 90%) remained
on antihypertensive monotherapy throughout the
study, presumably because their mild hypertensive
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Fig 2 | Clinic, 24 hour, daytime, and night-time systolic and diastolic blood pressure, showing mean values at baseline,
throughout treatment period, and at study end in patients taking pravastatin or corresponding placebo. All values during
treatment were always significantly different from those at baseline (P<0.001). Baseline and on-treatment values were not
significantly different between treatment groups
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Furthermore, restricting the analysis to patients on
monotherapy did not reveal any blood pressure low-
ering effect of pravastatin, even when we made adjust-
ment for the small difference in the rate of nifedipine
use between the placebo and the statin groups (12% v
13%). Finally, the time to event Kaplan-Meier analysis
didnotdetectanysignificantbetweengroupdifference
in the number of patients who needed open label nife-
dipine, and the clinic blood pressure values measured
three months after randomisation (that is, when the
protocolrequiredallpatientstostillbeoninitialmono-
therapy) were superimposable in the placebo and pra-
vastatin groups. This limitation thus does not detract
from the conclusion that pravastatin is devoid of a
blood pressure lowering effect.
A second limitation is that participants in PHYLLIS
were hypertensive and received antihypertensive
drugscapableofcausingaclearcutreductioninambu-
latory and clinic measured blood pressure. This
restricts our conclusion that statins do not exert any
significant blood pressure lowering effect to patients
with high blood pressure who receive effective anti-
hypertensive treatment.In other words, the possibility
remains that statins cause some reduction in blood
pressure when given alone—that is, in the absence of
a possible confounding effect of the antihypertensive
drug treatment. In this context, however, we should
mention that in PHYLLIS on-treatment ambulatory
andclinicbloodpressureremainedwellabovenormal
values,
1931 leaving a large potential for a further reduc-
tion in blood pressure to occur. This makes the above
possibility unlikely.
The third limitation relates to the suggestion from a
recently published cross sectional analysis that the
reductioninbloodpressurebystatinsismainlyevident
whentheinitialbloodpressureisparticularlyhigh(that
is, above the mild hypertension range explored in
PHYLLIS).
32 This suggestion is not in line with the
observation that in our patients no interaction
occurred between baseline blood pressure and the
effectsofpravastatinonbloodpressure.Inthiscontext,
we also emphasise that our study has a randomised
design, which, compared with cross sectional assess-
ment of drug effects, produces results that are much
lessaffected by many confoundersthat are never com-
pletely accounted for in statistical analysis.
Finally, our conclusion obviously refers to data
obtained with pravastatin, which means that a blood
pressure lowering effect of other statins cannot be
ruled out. However, virtually all cardiovascular effects
attributable to statins have been documented for more
than one drug and are therefore reported as common
totheclass,
33andthestudiesthathavereportedastatin
relatedbloodpressurereductionhaveusedpravastatin
as well as of other statins with no evidence of a differ-
ential effect on blood pressure.
10-17 Furthermore, in
PHYLLIS pravastatin was used at a dose (40 mg
daily) similar to that used in the studies that have
reported blood pressure lowering by statins. This
dosage caused a marked lipid lowering effect (reduc-
tion in serum low density lipoprotein cholesterol
greater than 1 mmol/l or 40 mg/dl), in line with what
is commonly observed with effective doses of any
statin.
Comparison with other studies
The data provided by PHYLLIS do not confirm the
conclusion of previous studies that statins exert a
bloodpressureloweringeffect.
10-17However,theeffect
in these studies was relatively small, and in a recent
meta-analysis that pooled most available data it
amounted to no more than 2 mm Hg reduction in sys-
tolic blood pressure and 1 mm Hg reduction in diasto-
licbloodpressure.
18Also,the11studiesincludedinthe
meta-analysis were all small—the total number of
patients was only slightly greater (n=563) than the
number included in PHYLLIS alone (n=508)—and
the studies were of a short duration (mostly one to six
months; only two studies extended the treatment per-
iodtooneyear)andhadratherheterogeneousdesigns.
The results of PHYLLIS are also not in line with
those of the California San Diego Statin Study,
34
whichhasrecentlyreportedthatinabout1000patients
with hypercholesterolaemia administration of simvas-
tatin(20mgdaily)orpravastatin(40mgdaily)causeda
small (2-3 mm Hg) statistically significant reduction in
Table 2 |Blood pressure reductions by antihypertensive treatment in hypertensive patients
randomised to either placebo or pravastatin (intention to treat population). Values are mean
(95% confidence interval)
Antihypertensive treatment v baseline Difference
pravastatin
v placebo P value Placebo Pravastatin
Clinic measurements
Systolic blood pressure
(mm Hg)
-19.2(−20.6to−17.8) −18.1 (−19.5 to
−16.7)
1.0 (−0.9 to 3.0) 0.31
Diastolic blood
pressure (mm Hg)
−12.4 (−13.2 to
−11.7)
−12.8 (−13.5 to
−12.0)
−0.3 (−1.4 to 0.7) 0.54
Pulsepressure(mmHg) −6.7 (−7.9 to −5.6) −5.3 (−6.6 to −4.1) 1.4 (−0.3 to 3.0) 0.10
Heart rate (beats/min) −0.4 (−1.3 to 0.4) −0.3 (−1.2 to 0.6) 0.1 (−1.1 to 1.4) 0.82
24 hour ambulatory measurements
Systolic blood pressure
(mm Hg)
−8.7 (−10.3 to −7.0) −7.0 (−8.5 to −5.6) 1.6 (−0.6 to 3.8) 0.15
Diastolic blood
pressure (mm Hg)
−6.2 (−7.2 to −5.1) −5.0 (−6.0 to −4.1) 1.2 (−0.2 to 2.6) 0.11
Pulsepressure(mmHg) −2.5 (−3.4 to −1.6) −2.0 (−2.8 to −1.2) 0.4 (−0.7 to 1.6) 0.46
Heart rate (beats/min) −0.9 (−1.7 to −0.1) −0.4 (−1.2 to 0.4) 0.5 (−0.7 to 1.7) 0.41
Daytime measurements
Systolic blood pressure
(mm Hg)
−8.8 (−10.5 to −7.2) −7.3 (−8.8 to −5.8) 1.5 (−0.7 to 3.8) 0.18
Diastolic blood
pressure (mm Hg)
−6.4 (−7.5 to −5.3) −5.2 (−6.2 to −4.2) 1.2 (−0.3 to 2.7) 0.12
Pulsepressure(mmHg) −2.5 (−3.4 to −1.5) −2.1 (−2.9 to −1.3) 0.3 (−0.9 to 1.6) 0.58
Heart rate (beats/min) −0.7 (−1.6 to 0.1) −0.2 (−1.1 to 0.7) 0.5 (−0.7 to 1.8) 0.42
Night-time measurements
Systolic blood pressure
(mm Hg)
−7.4 (−9.3 to −5.6) −5.6 (−7.2 to −3.9) 1.9 (−0.6 to 4.3) 0.13
Diastolic blood
pressure (mm Hg)
−5.1 (−6.3 to −3.9) −4.0 (−5.0 to −2.9) 1.1 (−0.4 to 2.7) 0.15
Pulsepressure(mmHg) −2.3 (−3.3 to −1.4) −1.6 (−2.5 to −0.7) 0.7 (−0.6 to 2.0) 0.27
Heart rate (beats/min) −1.2 (−2.1 to −0.4) −0.7 (−1.5 to 0.2) 0.6 (−0.6 to 1.7) 0.34
RESEARCH
6 BMJ | 2010 | VOLUMEsystolic blood pressure. Because this effect was seen in
patientswhowerenotreceivingantihypertensivetreat-
ment (most patients were normotensive), these results
are compatible with the above mentioned possibility
thatstatinsexertasmallbloodpressureloweringeffect
that can be detected only when they are given alone
and the masking effect of the more powerful anti-
hypertensive drugs is avoided. However, treatment
was short lasting in this study (six months), only clinic
measured blood pressure was available, and blood
pressure measurements were rare and obtained with
an aneroid device, the accuracy of which is question-
able.
Ourfindingsareinlinewithsomelargescalestudies
that have explored the blood pressure lowering effect
of statins over a longer follow-up period, although
never by ambulatory blood pressure monitoring. In
the Anglo-Scandinavian Cardiac Outcomes Trial—
Lipid Lowering Arm (ASCOT-LLA) in more than
10000hypertensivepatientswithaserumtotalcholes-
terol of 6.5 mmol/l (250 mg/dl) or below, the addition
of atorvastatin to an effective antihypertensive
Table 3 |Blood pressure reductions in placebo and pravastatin groups in subset of patients who remained on
antihypertensive monotherapy (hydrochlorothiazide 25 mg once daily or fosinopril 20 mg once daily) throughout study.
Values are mean (95% confidence interval)
Antihypertensive monotherapy v baseline Difference pravastatin
v placebo
Adjusted difference
pravastatin v placebo* P value Placebo (n=198) Pravastatin (n=199)
Clinic measurements
Systolic blood pressure
(mm Hg)
−19.6 (−21.2 to −18.0) −18.8 (−20.2 to −17.3) 0.8 (−1.3 to 2.9) 1.1 (−3.1 to 3.1) 0.44
Diastolic blood pressure
(mm Hg)
−12.7 (−13.6 to −11.9) −12.9 (−13.7 to −12.0) −0.1 (−1.3 to 1.0) −0.3 (−0.8 to 0.8) 0.83
Pulse pressure (mm Hg) −6.9 (−8.2 to −5.6) −5.9 (−7.2 to −4.6) 1.0 (−0.9 to 2.8) −0.3 (−0.8 to 0.8) 0.30
24 hour ambulatory measurements
Systolic blood pressure
(mm Hg)
−7.8 (−9.5 to −6.1) −6.3 (−7.8 to −4.7) 1.6 (−0.7 to 3.9) 1.5 (−3.7 to3.7) 0.18
Diastolic blood pressure
(mm Hg)
−5.7 (−6.8 to −4.6) −4.6 (−5.6 to −3.5) 1.2 (−0.3 to 2.7) 1.1 (−2.5 to 2.5) 0.12
Pulse pressure (mm Hg) −2.1 (−3.2 to −1.0) −1.7 (−2.6 to −0.8) 0.4 (−0.9 to 1.7) 0.4 (−1.6 to 1.6) 0.56
*Adjusted for difference between groups in proportion of participants on monotherapy.
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Fig 3 | Average serum lipid concentrations in patients taking pravastatin or corresponding placebo at baseline and throughout
treatment period. Data are means and standard deviations; P values refer to overall treatment effect in analysis of covariance.
In groups randomised to receive pravastatin in combination with either hydrochlorothiazide or fosinopril, total cholesterol and
low density lipoprotein cholesterol during treatment were always significantly lower than at baseline (P<0.001)
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BMJ | 2010 | VOLUME 7treatment regimen was accompanied by a clear cut
reduction in total serum cholesterol without any sub-
stantial effect on clinic measured blood pressure.
22
Similarly, no blood pressure lowering effect of pravas-
tatinatdosescapableofeffectivelyimprovingthelipid
profilewasreportedbyarecentanalysisoftheCholes-
terol and Recurrent Events (CARE) trial.
35
Finally,theresultsofPHYLLIScomplementtheevi-
dence provided by a substudy of ASCOT, in which
centralbloodpressurewasderivedfromtheperipheral
blood pressure signal by using a Sphygmocor device,
the Conduit Artery Function Evaluation—Lipid-
Lowering Arm (CAFE-LLA) study. Central blood
pressure was similar in patients taking atorvastatin or
placebo, thus again providing no evidence of a blood
pressure lowering effect.
36
Conclusions
The results of PHYLLIS show that at doses which
markedly lower serum total cholesterol and low den-
sity lipoprotein cholesterol, pravastatin does not exert
a lowering effect on systolic and diastolic blood pres-
sure measured in patients with hypertension and
hypercholesterolaemia who are receiving anti-
hypertensive treatment. It further shows that this is
the case for both clinic measured and ambulatory
blood pressure over short and long term (about three
years) administration of the drug. The protective
cardiovascular effects of pravastatin and, most likely,
of all statins are thus unlikely to depend on an anti-
hypertensive effect of these drugs.
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